Cell-based therapy in ischemic stroke.
Cell-based therapy in ischemic stroke.
复制标题
缺血性中风的基于细胞的疗法。
DOI：
10.1586/14737175.8.8.1193
复制
发表时间：
2008-08
影响因子：
4.3
通讯作者：
Borlongan CV
中科院分区：
文献类型：
--
作者：
Hess DC;Borlongan CV
基于细胞的中风疗法代表了中风疗法的第三波浪潮，该疗法专注于恢复过程，其机会窗口比神经保护疗法更长。中风后第一周内的早期时间窗口是静脉注射骨髓和围产期衍生细胞的机会，这些细胞可以定位组织损伤区域并针对大脑重塑。同种异体细胞可能是最具规模化和商业可行性的产品。稍后的时间窗口，即中风后几个月，可能是神经元分化细胞类型脑内移植的机会。需要一种基于细胞的治疗与早期临床试验和持续的临床前工作的综合方法，重点关注作用机制。
Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone-marrow and perinatally-derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally-differentiated cell types. An integrated approach of cell-based therapy with early phase clinical trials and continued pre-clinical work with focus on mechanisms of action is needed.